CTOs on the Move

ScribeAmerica

www.scribeamerica.com

 
ScribeAmerica is a Lancaster, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Hoosier

Hoosier is a Corona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Defyned Brands

Headquartered in Austin, we started as a single store with a mission to deliver outstanding results for our customers by providing supplements with the best-in-class ingredients and putting the customer`s experience first. Now more than 10 years later, we have evolved into Defyned Brands, a product development, brand marketing, and multi-channel retail company, owning 5 lifestyle supplement brands and over 50 retail stores under the name 5 Star Nutrition. We are passionate about putting our customers first by helping them reach their health and wellness potential.

EcoNugenics

EcoNugenics® was founded in 1995 by Dr. Isaac Eliaz, M.D., M.S., L.Ac. - a pioneer and expert in the field of integrative medicine, and a highly regarded clinical practitioner, formulator, researcher and author. Dr. Eliaz leads our research activities in natural, integrative approaches to cellular, immune, metabolic, digestive, and cardiovascular health, as well as detoxification.

The Public Health Foundation of Columbia County

The Public Health Foundation of Columbia County is a Saint Helens, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.